BioGaia AB (BIOGY)
12.08
0.00 (0.00%)
USD |
OTCM |
Jun 25, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.220B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 29.87% |
| Valuation | |
| PE Ratio | 34.56 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 9.906 |
| Price to Book Value | 5.994 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.6404 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.24% |
Profile
| BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas. |
| URL | https://www.biogaia.se |
| Investor Relations URL | https://www.biogaia.com/investors/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jul. 23, 2024 |
| Last Earnings Release | May. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2024 |
Ratings
Profile
| BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas. |
| URL | https://www.biogaia.se |
| Investor Relations URL | https://www.biogaia.com/investors/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jul. 23, 2024 |
| Last Earnings Release | May. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 09, 2024 |